Car T Cell Therapy Market Segmented By Yescarta, Kymriah, JCAR017, bb2121 Product with Relapsed Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma Indication
Report ID: PMRREP28264
Number of Pages: 150
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: November-2021
The global CAR T-cell therapy market was valued at US$ 1.2 Bn in 2020, and is anticipated to reach US$ 2.8 Bn by 2031, which equates to a CAGR of 5.6% over the forecast period (2021-2031), according to Persistence Market Research industry study.
CAR T-cell therapy is a type of T-cell therapy or a treatment to fight against cancer cells, holding approximately 27% market share in the overall T-cell therapy market.
Increasing prevalence of cancer is expected to drive production of CAR T-cells for use in therapeutic areas. Potential application of artificial T-cell receptors for the treatment of a wide variety of cancers has been widely acknowledged. Use of chimeric immunoreceptors is increasing because they aid T-cells in finding and killing cancer cells that have the specific protein to which receptor can bind.
There is continuous growth being seen in research & development in the life science and biotechnology sectors for the treatment of cancer using chimeric antigen receptors. Studies are increasing for validating the effectiveness of CAR T-cell therapy in various countries, which will help in improving data availability regarding the efficacy, mechanism of action, and compliance in patients suffering from leukemia and lymphoma.
| Attributes | Key Insights |
|---|---|
|
CAR T-Cell Therapy Market Value (2020) |
US$ 1.2 Bn |
|
Forecasted Market Size (2031) |
US$ 2.8 Bn |
|
2021-2031 Projected Growth Rate |
5.6% CAGR |
|
Share of Top 5 Countries |
93% |
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get Report SampleAccording to Persistence Market Research, the market for CAR T-cell therapy increased at a robust rate from 2016 to 2020. This was due to rising adoption of CAR T-cell as therapy for the treatment of cancer.
Manufacturing of CAR T-cells begins from the extraction of T-cells from patient followed by apheresis, and then sending the patient T-cells to the manufacturing facility. Currently, few manufacturing facilities can produce CAR T-cells and they are predominantly located in the U.S. and Europe.
Also, many manufacturers have started investing and expanding their manufacturing of CAR T cells owing to the growing need for cell-based therapy. After the approval of CAR T-cell therapy in 2017, key players of life science such as Novartis, Gilead, and Bristol Myers Squibb started manufacturing CAR T-cell products.
Persistence Market Research expects the global CAR T-cell therapy market to expand at a CAGR of 5.6% through 2031, mainly attributed to rising number of clinical trials for CAR T-cells, key players’ involvement in manufacturing, and ever-increasing need for cancer therapy.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionCAR T-cell therapy is a type of therapy in which the T-cells are taken from the blood of the patient, which is then modified in a lab by the addition of a gene for a man-made receptor (chimeric antigen receptor). This aids in better recognizing of specific cancer cell antigens. The CAR T-cells are then given back to the patient.
Different cancers have different antigens, and that is why each CAR T-cell is prepared for specific cancer antigens. This therapy is FDA-approved for treating cancer. Thus, it gives a great opportunity to manufacturers to invest and create great revenue from artificial antibody receptor CAR T-cell therapy for targeting cancer cells.
Increasing emphasis on research & development therapies for cancers, such as lung cancer, colorectal cancer, multiple myeloma cancer, and prostate cancer, is likely to create significant growth opportunities CAR T-cell therapy providers. Also, acquisitions can significantly accelerate a manufacturer’s strategy to capitalize and capture a significant share in the market.
Favorable government policies for life science companies and government funding are expected to boost CAR T-cell therapy demand in the near future.
Also, demand for novel treatment options for cancer is further expected to offer significant revenue generation opportunities to participants in the chimeric immunoreceptor therapy market.
Will the U.S. Remain a Key Market for Car T-Cell Therapy?
In 2021, the U.S. is estimated to account for over 98% value share in the North American market. Demand is increasing in the U.S due to rising number of life sciences companies focusing on the development and commercial manufacturing of CAR T-cells and improvement in quality control systems in North America.
Why is Germany the Lucrative Market for Car T-Cell Therapy in Europe?
Germany is expected to account for nearly 27% of the market share in Europe by 2031. Rise in demand for CAR T-cell therapy in Germany is primarily due to increasing geriatric population, which is at a higher risk of suffering from cancer and other diseases. Furthermore, favorable regulatory scenario is likely to offer new opportunities for Car T-cell therapy product manufacturers in Germany.
Why is Demand for Yescarta (axicabtagene ciloleucel) Rising Rapidly?
In terms of product, Yescarta (axicabtagene ciloleucel) holds a high share of over 57% in 2021. Yescarta (axicabtagene ciloleucel) is a treatment for large B-cell lymphoma, which is used when conventional treatment methods do not work effectively.
Large B-Cell Lymphoma Holds highest Market Share by Indication?
In terms of indication, relapsed large B-cell lymphoma holds approximately 90% market share in 2021. This is a condition when the lymphoma does not respond to treatment or when the response to treatment lasts for a short period.
The COVID-19 lockdown caused disruptions in the supply chain and discontinued business operations, which left many life science and biopharma companies waiting for the availability of new batches of raw material for CAR T-cell production.
The lockdown impact hampered life science and biopharmaceutical production activities due to shortage of manpower, which also restrained the growth of the end-user segment market. But this was a short-term impact and steady growth is expected over the coming years with the situation getting back to normal.
Companies providing CAR T-cell therapy are vigorously seeking to strengthen their position through collaborations, approvals, acquisitions, and agreements with established as well as emerging market players.
| Attribute | Details |
|---|---|
|
Forecast Period |
2021-2031 |
|
Historical Data Available for |
2016-2020 |
|
Market Analysis |
USD Million for Value. |
|
Key Countries Covered |
|
|
Key Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Product
Indication
End User
We make every effort to deliver the reports as soon as possible. Most reports are delivered within 1 to 2 weeks from order confirmation, though some may take longer depending on the scope.
The global CAR T-cell therapy market was worth US$ 1.2 Bn in 2020, and is set to expand 2.2X over the next ten years.
CAR T-cell therapy is projected to reflect high demand at a CAGR of 5.6% through 2031.
Regional manufacturing facility expansion, small manufacturers evaluating CAR T-cell therapy, and changing reimbursement scenario are major trends in this market space.
The U.S., Germany, France, U.K., and Italy are the top 5 countries driving most demand for CAR T-cell therapy.
North America currently holds the largest global market share of around 68%, with the U.S. being the leading contributor.
Europe is expected to enjoy a market share of approximately 29.3% in 2021.
Gilead Sciences, Inc., Novartis AG, and Celgene Inc. are key manufacturers of CAR T-cell therapy equipment.
The Japanese market is expected to have a market share of nearly 3% of the overall market share during the forecast period.
